Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carcinoma, Yale New Haven Hospital, discusses potential challenges nurses might face with the new advent on immunotherapy.
Matthew Burke, MBA, RN, MSN, APRN-BC
Advertisement
Articles by Matthew Burke, MBA, RN, MSN, APRN-BC
Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carcinoma, Yale New Haven Hospital, discusses managing immune-mediated adverse events (IMAEs)
Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carcinoma, Yale New Haven Hospital, discusses the difference between adverse events caused by chemotherapy and immunotherapy.
Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carincoma, Yale-New Haven Hospital, discusses the prevalence of immunotherapy-related adverse events.
Advertisement
Latest Updated Articles
Matthew Burke on the Prevalence of Immunotherapy AEsPublished: February 7th 2014 | Updated:
Matthew Burke Discusses Adverse EventsPublished: March 5th 2014 | Updated:
- Matthew Burke on Potential Challenges Facing Nurses in the Field of Immunotherapy
Published: August 25th 2014 | Updated:
- Matthew Burke on Immune-Mediated Adverse Events
Published: May 5th 2014 | Updated:
Advertisement
Advertisement
Trending on Oncology Nursing News
1
How Using Gender-Neutral Language Can Open Goals of Care Conversations
2
Physical Activity Supervision Does Not Up QOL in Metastatic Cancer
3
Improving Access to Supportive Care on an Organizational Level, With Korie Bigbee
4
